Securities code: 603313 securities abbreviation: Healthcare Co.Ltd(603313) Announcement No.: 2022-002 Healthcare Co.Ltd(603313)
Announcement of annual performance loss in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The company's performance is expected to realize the net profit attributable to the shareholders of the listed company in 2021, with a loss of 24 million yuan - 300 million yuan, a decrease of 619 million yuan - 679 million yuan compared with the same period of last year, a year-on-year decrease
163%-179%。
After deducting non recurring gains and losses, the company's performance is expected to decrease by 506 million yuan to 566 million yuan, a year-on-year decrease of 145% - 162%.
1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
1. According to the preliminary calculation of the financial department, it is expected that there will be a loss in the annual operating performance in 2021, and the net profit attributable to the shareholders of the listed company will be a loss of 24 million yuan - 300 million yuan, a decrease of 619 million yuan - 679 million yuan, a year-on-year decrease of 163% - 179%.
2. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses is 156 million yuan to 216 million yuan, which will decrease by 506 million yuan to 566 million yuan compared with the same period of last year, a year-on-year decrease of 145% - 162%.
2、 Performance in the same period of last year
(I) net profit attributable to shareholders of the listed company: 37858585700 yuan. Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses: 349.918 million yuan.
(II) earnings per share: 1.11 yuan.
3、 Main reasons for performance loss in advance in the current period
1. During the reporting period, the prices of raw materials, labor costs and overseas transportation costs of the company increased significantly, resulting in a decline in the gross profit margin of the company's products and affecting the profits of the current period;
2. In recent years, Global trade protection measures have proliferated and trade frictions among major economies have continued. The US Department of Commerce issued the arbitration results of the second round of anti-dumping investigation in March 2021. Healthcare Europe dooruma, a wholly-owned subsidiary of the company (hereinafter referred to as "Hengkang Serbia"), applies the tax rate of 112.11%. Hengkang Serbia was originally mainly supplied to the US market. Affected by the US anti-dumping tax, the company timely adjusted the production capacity of its subsidiaries to mainly supply to the European market. However, due to the European market blockade in the first half of 2021, the production and sales of Hengkang Serbia decreased significantly, which affected the performance of the company to a certain extent;
3. The Meidong and Meixi plants of the company are in the production capacity climbing period. Affected by the epidemic, the production schedule of the two plants is lower than expected, resulting in losses during the reporting period;
4. On September 2, 2021, the company disclosed the announcement on the progress of litigation (Announcement No.: 2020-53) on the website of Shanghai Stock Exchange. The company won the first instance judgment in the lawsuit with Benjamin folkins (a minority shareholder of China bedsdirect, LLC, an American subsidiary of the company) and upward mobility, Inc. (a company controlled by Benjamin folkins). According to the accounting standards for business enterprises and relevant regulations, the company accrued estimated liabilities for the equity withdrawal and punitive damages in the amount involved, and the impact on profits was about 160 million yuan;
5. In accordance with the accounting standards for Business Enterprises No. 22 - recognition and measurement of financial instruments and relevant accounting policies, bad debt reserves are withdrawn for single significant assets with signs of impairment.
4、 Risk tips
Up to now, the litigation between the company and Benjamin folkins and upward mobility, Inc. is still in the process of appeal. If there are further results of the follow-up litigation, the estimated liabilities may be adjusted according to the latest results, thus affecting the content of this performance forecast. In addition to the above, the company has no major uncertain factors affecting the accuracy of the performance forecast.
5、 Other explanatory matters
The above forecast data are only preliminary accounting data and have not been audited by the audit institution. The specific and accurate financial data are subject to the audited 2021 annual report officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Healthcare Co.Ltd(603313) board of directors January 28, 2022
